The TAILORx study demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype Dx test do not need chemotherapy after surgery. These findings will spare thousands of women from the harmful effects of chemotherapy. We spoke with Andrew Paramore from Genomic Health (CA, USA)to discover insider details of the trial and what’s next for TAILORx.